Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GLORA phase 3 study of lisaftoclax in previously treated CLL/SLL
2023-508005-24-00Phase 3Authorised
- Sponsor
- Ascentage Pharma
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, randomised, open-label trial of lisaftoclax in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Ascentage Pharma. Primary endpoint: Progression-free survival assessed by independent review committee. Planned start Aug 2024; status: authorised.
02
Drugs
lisaftoclax
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2023-508005-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508005-24-00.